| Size | Price | Stock | Qty |
|---|---|---|---|
| 100g |
|
||
| 250g |
|
||
| Other Sizes |
| Targets |
2,6-Dimethoxybenzaldehyde inhibits the survival of J-774 cells and Mycobacterium tuberculosis, suggesting that it may target cellular processes essential for cell survival and bacterial growth. J-774 is a murine macrophage cell line, and the compound's ability to inhibit its survival suggests potential immunomodulatory or cytotoxic effects. The compound's activity against Mycobacterium tuberculosis indicates that it may target essential bacterial proteins or metabolic pathways, making it a potential lead compound for antitubercular drug development. The compound is also used in the synthesis of thiazolidin-4-one derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors, which target the reverse transcriptase enzyme of HIV-1, blocking viral replication. The compound's aldehyde group allows it to form Schiff bases and other derivatives that may interact with various biological targets.
|
|---|---|
| ln Vitro |
In vitro, 2,6-dimethoxybenzaldehyde inhibits the survival of J-774 cells and Mycobacterium tuberculosis. It is used in the synthesis of thiazolidin-4-one derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors. The compound's aldehyde group allows for demethylation with AlBr3 to prepare 2,6-dihydroxybenzaldehyde. It is a biochemical reagent that can be used as a biological material or organic compound for life science related research. In medicinal chemistry, it serves as a versatile building block for constructing biologically active molecules. Its reactivity allows for the formation of various derivatives through condensation, cyclization, and functional group transformations.
|
| ln Vivo |
In vivo activity has not been directly studied for the parent compound 2,6-dimethoxybenzaldehyde. However, its derivatives, such as thiazolidin-4-one derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors, are evaluated in animal models of HIV infection. The compound's activity against Mycobacterium tuberculosis suggests potential for in vivo evaluation in animal models of tuberculosis, but specific studies on the parent compound are limited. The parent compound is not typically administered in vivo, as it is a synthetic intermediate rather than a pharmacological agent.
|
| Enzyme Assay |
Cell-free assays involving 2,6-dimethoxybenzaldehyde are focused on its use as a chemical reagent. Standard protocols for demethylation involve reacting the compound with AlBr3 to prepare 2,6-dihydroxybenzaldehyde. For aldehyde derivatization, the compound is reacted with amines to form imines or with other nucleophiles in condensation reactions. The reaction progress is monitored by TLC or HPLC. For the synthesis of thiazolidin-4-one derivatives, the compound is used as a starting material in multi-step synthetic routes. The compound's reactivity can be studied using various analytical techniques, including NMR spectroscopy and mass spectrometry.
|
| Cell Assay |
Cellular assays with 2,6-dimethoxybenzaldehyde have demonstrated that it inhibits the survival of J-774 cells. In these assays, J-774 macrophage cells are treated with the compound at various concentrations, and cell viability is measured using MTT or similar assays. The compound's activity against Mycobacterium tuberculosis is evaluated in microbiological assays, where bacterial cultures are treated with the compound, and growth inhibition is measured. The compound's derivatives, such as thiazolidin-4-one derivatives, may be evaluated in cell-based systems for antiviral activity.
|
| Animal Protocol |
Animal studies are not typically conducted with the parent compound 2,6-dimethoxybenzaldehyde. Its derivatives, such as thiazolidin-4-one derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors, are evaluated in animal models of HIV infection. The compound's activity against Mycobacterium tuberculosis suggests potential for in vivo evaluation in animal models of tuberculosis, but specific studies on the parent compound are limited. The parent compound is not administered to animals, as it is a synthetic intermediate.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for 2,6-dimethoxybenzaldehyde are not available. As a small lipophilic aldehyde with a molecular weight of 166.18 g/mol and an estimated LogP of approximately 2.0, it is expected to have moderate membrane permeability if administered, but it is not intended for therapeutic use. Comprehensive pharmacokinetic studies have not been performed, as the compound is not intended for systemic administration. For research purposes, the compound is typically handled as a neat chemical and not administered to living organisms for pharmacokinetic profiling.
|
| Toxicity/Toxicokinetics |
Toxicological data for 2,6-dimethoxybenzaldehyde are limited. Standard safety precautions for handling aromatic aldehydes apply, including the use of personal protective equipment such as gloves and safety goggles. The compound should be handled in a well-ventilated area, and contact with skin and eyes should be avoided. In case of exposure, affected areas should be rinsed thoroughly with water. The compound is not classified as a carcinogen or mutagen based on available data, but comprehensive toxicological evaluation has not been performed. The compound has not been fully validated for medical applications and is for research use only. As with all research chemicals, it should be handled with care and used only in accordance with safety guidelines.
|
| Additional Infomation |
2,6-Dimethoxybenzaldehyde is a research chemical, not an approved drug. It has no clinical trial or marketing approval status for therapeutic use. The compound inhibits the survival of J-774 cells and Mycobacterium tuberculosis and can be used in the study of tuberculosis. It is used in the synthesis of thiazolidin-4-one derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors. The compound is a widely used reactant and can be demethylated with AlBr3 to prepare 2,6-dihydroxybenzaldehyde. It is a biochemical reagent that can be used as a biological material or organic compound for life science related research. It is supplied with a purity of ≥98% and should be stored in a cool, dry place. The product has not been fully validated for medical applications and is for research use only.
|
| Molecular Formula |
C9H10O3
|
|---|---|
| Molecular Weight |
166.17
|
| Exact Mass |
166.062
|
| CAS # |
3392-97-0
|
| PubChem CID |
96404
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
289.6±20.0 °C at 760 mmHg
|
| Melting Point |
96-98 °C(lit.)
|
| Flash Point |
119.8±8.2 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.534
|
| LogP |
1.67
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
12
|
| Complexity |
135
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O(C)C1C=CC=C(C=1C=O)OC
|
| InChi Key |
WXSGQHKHUYTJNB-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C9H10O3/c1-11-8-4-3-5-9(12-2)7(8)6-10/h3-6H,1-2H3
|
| Chemical Name |
2,6-dimethoxybenzaldehyde
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.0179 mL | 30.0897 mL | 60.1793 mL | |
| 5 mM | 1.2036 mL | 6.0179 mL | 12.0359 mL | |
| 10 mM | 0.6018 mL | 3.0090 mL | 6.0179 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
